DRUG DELIVERY MATRICES TO ENHANCE WOUND HEALING
    1.
    发明申请
    DRUG DELIVERY MATRICES TO ENHANCE WOUND HEALING 审中-公开
    药物递送矩阵,以加强伤口愈合

    公开(公告)号:US20070202178A1

    公开(公告)日:2007-08-30

    申请号:US11739607

    申请日:2007-04-24

    IPC分类号: A61K9/00

    摘要: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGFβ superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.

    摘要翻译: 生物活性分子被包埋在基质内,用于受控递送这些化合物用于治疗性愈合应用。 基质可以由天然或合成的化合物形成。 捕获生物活性分子的主要方法是通过体外或体内在基质凝胶化过程中沉淀生物活性分子。 可以修饰生物活性分子以降低其在基质中的有效溶解度,从而更有效地将其保留在基质内,例如通过胱氨酸结生长因子超家族内,特别是在TGFbeta超家族内的成员的去糖基化。 可以修饰基质以包括对不同生物活性分子具有结合亲和力的位点,例如用于肝素结合的位点。

    Synthetic matrix for controlled cell ingrowth and tissue regeneration
    2.
    发明申请
    Synthetic matrix for controlled cell ingrowth and tissue regeneration 审中-公开
    用于受控细胞向内生长和组织再生的合成基质

    公开(公告)号:US20050065281A1

    公开(公告)日:2005-03-24

    申请号:US10494905

    申请日:2002-11-07

    摘要: Biomaterial comprises a three dimensional polymeric network obtainable from the reaction of at least a first and second precursor molecule. The first precursor molecule is at least a trifunctional, branched component comprising at least three arms substantially similar in molecular weight and the second precursor molecule is at least a bifunctional component The ratio of equivalent weight or the functional groups of the first and second precursor molecule is in a range of between 0.9 and 1.1. The molecular weight of the arms of the first precursor molecule. the molecular weight of the second precursor molecule and the functionality of the branching points are selected so that the water content of the polymeric networks is between the equilibrium weight % and 92 weitht of the total weight of the polymeric network after completion of water uptake. The present invention teaches a way to improve characteristics of synthetic matrices which are useful for wound healing applications.

    摘要翻译: 生物材料包括可从至少第一和第二前体分子的反应获得的三维聚合物网络。 第一前体分子是至少三官能的支化组分,其包含分子量基本上相似的至少三个臂,第二前体分子至少是双功能组分。第一和第二前体分子的当量重量或官能团的比例是 在0.9到1.1的范围内。 第一前体分子的臂的分子量。 选择第二前体分子的分子量和支化点的官能度,使得聚合物网络的水含量在完成吸水后聚合物网络的总重量的平衡重量%和92之间。 本发明教导了一种改善可用于伤口愈合应用的合成基质的特性的方法。

    Synthetic Matrix for Controlled Cell Ingrowth and Tissue Regeneration
    3.
    发明申请
    Synthetic Matrix for Controlled Cell Ingrowth and Tissue Regeneration 审中-公开
    用于受控细胞生长和组织再生的合成基质

    公开(公告)号:US20070264227A1

    公开(公告)日:2007-11-15

    申请号:US11735263

    申请日:2007-04-13

    IPC分类号: A61K31/74

    摘要: Biomaterials containing a three-dimensional polymeric network formed from the reaction of a composition containing at least a first synthetic precursor molecule having n nucleophilic groups and a second precursor molecule having m electrophilic groups wherein the sum of n+m is at least five and wherein the sum of the weights of the first and second precursor molecules is in a range from about 8 to about 16% b weight of the composition, preferably from about 10 to about 15%, more preferably from about 12 to about 14.5% by weight of the composition. In one embodiment, the first and second precursor molecules are polyethylene glycols functionalized with nucleophilic and electrophilic groups, respectively. In a preferred embodiment, the nucleophilic groups are amino and/or thiol groups and the electrophilic groups are conjugated, unsaturated groups. The ratio of the equivalent weights of the electrophilic groups (second precursor molecule) and the nucleophilic groups (first precursor molecule) is in the range of between 0.7 and 1.1, more preferably between 0.8 and 1.0. The first and/or second precursor molecule may be covalently bound to one or more molecules selected from the group consisting of cell adhesion peptides, growth factors, and growth factor-like peptides.

    摘要翻译: 包含由包含至少具有n个亲核基团的第一合成前体分子和具有m个亲电子基团的第二前体分子的组合物的反应形成的三维聚合物网络的生物材料,其中n + m的总和至少为5,并且其中 第一和第二前体分子的重量的总和在组合物的约8至约16重量%的范围内,优选约10至约15重量%,更优选约12至约14.5重量% 组成。 在一个实施方案中,第一和第二前体分子是分别用亲核基团和亲电子基团官能化的聚乙二醇。 在优选的实施方案中,亲核基团是氨基和/或硫醇基团,亲电基团是共轭的,不饱和基团。 亲电子基团(第二前体分子)和亲核基团(第一前体分子)的当量重量比在0.7和1.1之间,更优选在0.8和1.0之间。 第一和/或第二前体分子可以共价结合到选自细胞粘附肽,生长因子和生长因子样肽的一种或多种分子。

    GROWTH FACTOR MODIFIED PROTEIN MATRICES FOR TISSUE ENGINEERING
    4.
    发明申请
    GROWTH FACTOR MODIFIED PROTEIN MATRICES FOR TISSUE ENGINEERING 有权
    生长因子改良组织工程蛋白质矩阵

    公开(公告)号:US20070179093A1

    公开(公告)日:2007-08-02

    申请号:US11679807

    申请日:2007-02-27

    摘要: Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g. rapidly near the living tissue interface and more slowly farther into the injury zone. Additional benefits include the lower total drug dose within the delivery system, and spatial regulation of release which permits a greater percentage of the drug to be released at the time of greatest cellular activity.

    摘要翻译: 将蛋白质掺入用于组织修复,再生和/或重塑和/或药物递送的蛋白质或多糖基质中。 可以掺入蛋白质,使其通过降解基质,通过酶作用和/或扩散来释放。 如实施例所示,一种方法是通过共价或非共价方法将肝素与基质结合,形成肝素基质。 然后肝素将肝素结合生长因子非共价结合到蛋白质基质上。 或者,可以构建融合蛋白,其包含交联区域,例如因子XIIIa底物和天然蛋白质序列。 当需要长期药物递送时,例如在神经再生的情况下,在基质和生物活性因子之间引入可降解的键可能是特别有用的,其中期望在空间上改变作为再生的功能的药物释放速率 ,例如 快速靠近生物组织界面,并进一步向进入损伤区更慢。 额外的益处包括递送系统内的总药物剂量越少,释放的空间调节,允许在最大的细胞活动时释放更多百分比的药物。

    Nanoparticles for immunotherapy
    9.
    发明申请
    Nanoparticles for immunotherapy 有权
    用于免疫治疗的纳米颗粒

    公开(公告)号:US20080031899A1

    公开(公告)日:2008-02-07

    申请号:US11707627

    申请日:2007-02-19

    IPC分类号: A61K39/00 A61K9/14 A61P43/00

    摘要: Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics.

    摘要翻译: 描述了在不存在生物分子的情况下激活补体的纳米颗粒。 显示了纳米颗粒特异性靶向抗原呈递细胞,特别是在淋巴结中,而不用生物分子进行靶向。 这些颗粒是用于递送免疫治疗剂的有用载体。